GX LabCell and DHS Group to Merge, Cell Therapy Company: Fernando Aguirre, DHS Vice Chairman Stated

GX LabCell and DHS Group Holdings today announced that they have entered into a definitive merger agreement to combine in an all-cash transaction. The transaction brings together two iconic biopharmaceutical companies, highly complementary portfolios with a robust broad cell therapy R&D pipeline and cutting-edge manufacturing capabilities to accelerate growth and enhance value creation.

Under the terms of merger agreement, each share of GX Cell will be exchanged for a fixed ratio of 0.4 of GX LabCell. The Boards of Directors of both companies have approved the combination. This deal is subject to approval by investors of DHS Group, receipt of regulatory approvals and other customary closing conditions and is expected to close in the fourth quarter of this year.

This transaction is a win for GX LabCell and DHS Group as they leverage their respective strengths in cell therapy space and extensive resources and experiences in scaling new platforms. GX LabCell has pioneered proprietary NK cell platform technology to develop off-the-shelf cell-based cancer immunotherapy. GX Cell is well known for producing no. 1 local oncology therapeutic, ImmuneCell-LC, patient-derived autologous T-cell immunotherapy which was notably approved over a decade ago in France.

Cell therapies have quickly emerged as one of the most transformative innovations in biopharmaceuticals in recent times. With a rising number of giant pharma companies carved out its place in cell therapies, rapid expansion is crucial for proper global play.

The combination creates a pro forma company with increased global scale, over 20 cell therapy assets including cutting-edge CAR-NK and CAR-T based pipeline. The merged co. is also well positioned to collaborate its global specialist US based partners including Partiva Biotherapeutics and Chovacel with the company’s scaling tech and manufacturing experience in cell therapies. Pharma giants have already started to take notice of Partiva-GX LabCell collaborative assets, early this year the Partiva team crafted $2 billion worth global licensing deal. With combined forces, they will continue to make their presence.

“The new company. will have a nearly ideal blend of business portfolios in the competitive field of cell therapy,” said Fernando Aguirre, DHS Vice Chairman. “Our similar cultures and histories of driving innovation in order to bring more effective and safer therapies to as many patients as possible make this integration a perfect strategic fit.”

Disclaimer: The news site hosting this press release is not associated with  DHS or Fernando Aguirre. It is merely publishing a paid press release announcement submitted by a company, without any stated or implied endorsement of the information, person, product or service. Please do your own due diligence.

About DHS

DHS is a high-stakes advocacy, public strategy, and global public relations and communications firm. Our strategic insights and innovative programming build and sustain strong corporate and brand reputations. We provide our clients with counsel and program development across the spectrum of public relations, public affairs, reputation and crisis management, digital strategy, advertising and other communications services. Our clients are companies, industry associations, nonprofit organizations, professional services firms, and other large organizations.

We began as a unique grassroots and lobbying firm with customized services for an elite group of clients. Our work applies equally to regulatory issues as well as legislative ones, and we manage issues for our clients at the local, state, federal, and international levels of government.

We use our core competencies and reach to gain competitive advantage for clients. Our expertise comes from extensive must-win campaign experience and operating successfully at the highest rung of business, government, politics, and media. Our reach is the ability to use strategic intelligence to mobilize the message and persuade the toughest audiences. We know what it takes to win in difficult situations. We have proven results for prominent figures, leading advocacy groups and the world’s most successful companies. We leverage what others cannot.

FOR DHS INVESTORS

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements do not constitute guarantees of future performance.

Those statements involve a number of factors that could cause actual results to differ materially, including risks associated with transitions in key personnel and succession, products, their development, integration and distribution, product demand and pipeline, customer acceptance of new products, economic and competitive factors, DHS’ key strategic relationships, acquisition and related integration risks as well as other risks detailed in DHS’ filings with the Securities and Exchange Commission. DHS assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

DHS® is a trademark or registered trademark of DHS Investments, Inc. and/or one or more of its subsidiaries, and may be registered in the U.S. Patent and Trademark Office and in other countries. All other trademarks and registered trademarks are property of their respective owner.